- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Exploring the Complex Nature of IgA Nephropathy
Explore the complexities of IgA nephropathy, its treatment advancements, and the challenges in early diagnosis and management in nephrology.
IgA nephropathy (IgAN) is a challenging disease to manage due to its heterogeneous presentation, unpredictable progression, and variable response to therapy. Patients may range from being asymptomatic with isolated hematuria to experiencing progressive kidney dysfunction leading to end-stage kidney disease. This clinical variability makes risk stratification and treatment decision-making difficult. In addition, disease progression often occurs slowly over many years, complicating early identification of patients who would benefit most from intervention. The absence of reliable biomarkers to accurately predict prognosis and treatment response further adds to the complexity. Together, these factors underscore the need for improved tools to personalize care and optimize long-term outcomes for patients with IgAN.
HEDIS Glycemic Goal Achieved Using Control-IQ Technology
December 22nd 2025A greater proportion of patients with type 1 diabetes who used automated insulin delivery systems vs multiple daily injections achieved the Healthcare Effectiveness Data and Information Set (HEDIS) glycemic measure.
Read More
